Summary: This week we explore 2 unrelated but possibly 'game changing' papers. First we delve into a very recent report on a novel intranasal therapy for acute termination of SVT. Then we review a recent report from the Boston Adult Congenital Heart Program (BACH) on a potential role for inflammation as a possible cause for poor outcomes in ACHD patients. Can inflammatory markers predict poor outcomes in ACHD patients as they do in non ACHD adult patients? Dr. Alexander Opotowsky, Associate Professor of Pediatrics at Harvard Medical School shares his insights into this very unusual and novel concept in the world of ACHD.
